Pretomanid (also known as PA-824) is a new drug for the treatment of multi-drug-resistant tuberculosis (MDR-TB). It is an oral nitroimidazole antibiotic and is used in combination with other anti-TB drugs. It works by killing the bacteria that cause tuberculosis. It has been approved by the US Food and Drug Administration (FDA) in 2019 for use in adults with extensively drug-resistant TB (XDR-TB). It is the first new anti-TB medicine to be approved by the FDA in more than 40 years. It is generally used as part of a combination treatment regimen for MDR-TB that also includes drugs such as bedaquiline, linezolid, and clofazimine.
Pretomanid is an antibiotic medication specifically used for the treatment of multi-drug-resistant tuberculosis (MDR-TB) affecting the lungs [1]. It's typically used in combination with other medications like bedaquiline and linezolid [1]. MDR-TB is a serious form of tuberculosis that is resistant to the most effective antibiotics used to treat the condition.
Pretomanid is a relatively new medication, having been granted FDA approval in August of 2019 [3]. It was the first TB drug developed by a non-profit organization, known as TB Alliance [3]. One of the significant advantages of Pretomanid is that it allows for a shorter treatment duration compared to other MDR-TB medications [13]. Additionally, it can be administered as an oral tablet, improving ease of use for patients [4].